Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons  by Zhao, Rong-Rong et al.
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Several  diseases  and  injuries  of  the  central  nervous  system  could  potentially  be  treated  by  delivery  of  an
enzyme,  which  might  most  effectively  be  achieved  by  gene  therapy.  In  particular,  the  bacterial  enzyme
chondroitinase  ABC  is  beneﬁcial  in  animal  models  of  spinal  cord  injury.  We  have  adapted  the  chondroiti-
nase  gene  so  that  it can  direct  secretion  of  active  chondroitinase  from  mammalian  cells,  and  inserted  iteywords:
entiviral vectors
hondroitinase ABC
orticospinal tract
pinal cord injury
xon regeneration
into  lentiviral  vectors.  When  injected  into  adult  rat  brain,  these  vectors  lead  to extensive  secretion  of
chondroitinase,  both  locally  and  from  long-distance  axon  projections,  with  activity  persisting  for  more
than  4  weeks.  In  animals  which  received  a simultaneous  lesion  of the  corticospinal  tract,  the  vector
reduced  axonal  die-back  and  promoted  sprouting  and  short-range  regeneration  of corticospinal  axons.
The same  beneﬁcial  effects  on damaged  corticospinal  axons  were  observed  in  animals  which  received
the  chondroitinase  lentiviral  vector  directly  into  the  vicinity  of  a spinal  cord  lesion.. Introduction
For several diseases and injuries of the central nervous system
CNS), potential forms of treatment would involve delivery of an
nzyme, which might most effectively be achieved by a gene ther-
py approach. One example is the bacterial enzyme chondroitinase
BC, which is under consideration as a possible treatment for spinal
Abbreviations: BDA, biotinylated dextran amine; CMV, cytomegalovirus; CNS,
entral nervous system; CS, chondroitin sulfate; CSPG, chondroitin sulfate proteo-
lycan; CST, corticospinal tract; DMEM,  Dulbecco’s modiﬁed Eagle’s medium; GAG,
lycosaminoglycan; LV-ChABC, lentiviral vector encoding chondroitinase ABC; PBS,
hosphate buffered saline; PGK, phosphoglycerate kinase.
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cord injury. Because of the potential risks of prolonged or repeated
infusions, we  wished to adapt the chondroitinase gene so that it
could direct secretion of active chondroitinase from mammalian
cells, and to deliver it using lentiviral vectors so that both neurons
and glia could secrete the enzyme.
The aim in using chondroitinase is to remove chondroitin sul-
fate proteoglycans (CSPGs), one of the major classes of inhibitory
molecule present in the scar that forms after injury and prevents
regeneration of damaged axons (Kwok et al., 2008). CSPGs consist
of a core protein with attached glycosaminoglycan (GAG) chains.
After CNS injury, CSPGs are synthesized by glial cells and create
a barrier impenetrable for axon regeneration. CSPGs also exist in
the uninjured CNS, particularly in matrix structures found around
the cell body and neurites of some neurons, known as perineu-
ronal nets. Perineuronal nets have a role in restricting plasticity;
removing CSPGs has been shown to restore CNS plasticity.
Chondroitinase ABC is a bacterial enzyme from Proteus vulgaris,
which degrades CSPGs by cleaving GAG chains, which are responsi-
Open access under CC BY license.ble for most of the inhibitory effect. Injection of chondroitinase into
the brain or spinal cord promotes circuit plasticity, due to sprouting
of axons and remodelling of intact circuits. Also, following spinal
cord injury, chondroitinase treatment can promote long-distance
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Table 1
Lentiviral vectors encoding modiﬁed chondroitinase ABC.
Name Promoter Lab Concentrationa Minimum titreb References
LV-C CMV Amsterdam 99 g/ml of P24 6 × 105 TU/l (HEK cells) Naldini et al. (1996a), Hendriks et al. (2007),
LV-D CMV London 1.44 × 109 gen/ml 8 × 105 TU/l (HEK cells) Dull et al. (1998), Yán˜ez-Mun˜oz et al., 2006
LV-P PGK Lausanne 479 g/ml of P24 ∼106 TU/l (SCTM cells) Déglon et al. (2000)
a gen: genomes, by Q-PCR.
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egrowth of axons. Both local sprouting and long-distance regen-
ration are accompanied by functional recovery (Bradbury et al.,
002; Kwok et al., 2008; Bradbury and Carter, 2011).
Delivery of the enzyme can entail practical problems. The half-
ife of the enzyme at 37 ◦C can vary considerably. Although it can
each 2–3 weeks with stabilizers such as albumin or trehalose (Chau
t al., 2004; Lee et al., 2010), it is much shorter in the absence of
uch agents, and the half-life was only 6 days in injected rat brain
Lin et al., 2008). A single injection can produce functional recov-
ry by local axon growth and circuit reorganization (Galtrey et al.,
007; Cafferty et al., 2008), but longer-range regrowth of axons
s likely to need more prolonged treatment, by chronic infusion
r repeated injections, as has been given in experiments where
ong-distance tracts were severed (Bradbury and Carter, 2011).
or eventual treatment of human patients, given the much larger
ize of the spinal cord and of the injured region, and the greater
mportance of the corticospinal tract, chondroitinase activity would
robably be required over several months. Chronic delivery carries
isks of tissue damage, inﬂammation, and infection.
Gene delivery of chondroitinase to the CNS could have several
dvantages. A long-lasting effect could be achieved with only a sin-
le injection, and any side-effects of injection, including the risk of
ausing further trauma and infection, would be minimized. Thus it
ould represent a powerful approach for promoting regeneration
f the spinal cord after injury.
However, achieving secretion of a bacterial protein by
ammalian cells can be problematic. As the newly synthe-
ized chondroitinase polypeptide passes through the eukaryotic
ecretion pathway, cryptic N-glycosylation sites can become gly-
osylated, and because the bacterial sequence is not adapted for
he eukaryotic pathway, this process can interfere with folding
nd secretion of the protein. We  found that this process led to
ailure of functional enzyme production from the original bacte-
ial chondroitinase gene when transfected into mammalian cells
Muir et al., 2010). We  therefore modiﬁed the chondroitinase gene
y directed mutagenesis of up to 6 selected N-glycosylation sites
hich mapped to positions important for structure or ligand bind-
ng. These mutations did not impair enzyme activity in vitro, and
hey allowed the translated protein to pass through the secretion
athway unimpaired, resulting in efﬁcient secretion of active chon-
roitinase from transfected cells in vitro (Muir et al., 2010).
For greater efﬁciency of expression in vivo, we have now inserted
he modiﬁed chondroitinase gene into three lentiviral vectors.
entiviral vectors have been shown to transduce both neurons and
lia efﬁciently in the CNS (Naldini et al., 1996b; Bloemer et al.,
997; Baekelandt et al., 2002; Zhao et al., 2003; Hendriks et al.,
007). In brain, expression is mainly in glia and leukocytes ini-
ially (Baekelandt et al., 2002), but also occurs in neurons from 2
eeks onwards (Bloemer et al., 1997; Baekelandt et al., 2002). In
pinal cord, injections into dorsal column white matter (Zhao et al.,
003) or into post-injury glial scar (Hendriks et al., 2007) trans-
uce all classes of glia, as well as many neurons in the surrounding
ray matter, for ≥14 days. Expression is sustained in some popula-
ions of neurons for up to a year, and there is minimal immune
esponse (Bloemer et al., 1997; Baekelandt et al., 2002). Such of cells positive by chondroitinase immuno-staining 3 days after transduction of a
vectors have been used successfully to deliver therapeutic trans-
genes to the rodent CNS in models of neurological disease (e.g. Dull
et al., 1998; Yán˜ez-Mun˜oz et al., 2006). Lentiviral vectors are thus
the present vector of choice for high-level long-term local expres-
sion of a transgene, both in glia which produce the axon-inhibitory
CSPGs, and in neurons which are affected by them.
Here we  report that cells transduced with these vectors secrete
active chondroitinase at high levels in tissue culture and in rat
brain, and that the chondroitinase action in a model of spinal cord
injury protects corticospinal axons from die-back and promotes
sprouting. These results suggest that lentiviral vector-mediated
expression of modiﬁed chondroitinase could form a useful com-
ponent of a future treatment for spinal cord injury.
2. Materials and methods
2.1. Chondroitinase gene
Previous studies in vitro and in tissue culture (Muir et al., 2010)
were used to design an optimized chondroitinase gene for secre-
tion of enzyme from mammalian cells. The best gene from those
studies was Y133, with 5 mutations, but we also found that muta-
tion N751Q (present in Y133) was  irrelevant as this residue is not
glycosylated, whereas mutation N338Q (present in a different con-
struct) appeared to have a slight extra beneﬁcial effect (data not
shown). We  therefore synthesized gene Y1330 with the mutations
N282K, N338Q, N345Q, S517A, N675Q (S517A abolishes glycosy-
lation at N515), with the coding sequence replaced with preferred
mammalian codons (Euroﬁns MWG  Operon, Germany). (The full
sequence is in Supplementary Data.) The signal sequence was from
mouse matrix metalloproteinase 2 (Muir et al., 2010). This gene
was  cloned into vector pcDNA3.1 and was conﬁrmed to produce
highly active chondroitinase by in vitro transcription/translation
and enzyme assay (data not shown).
2.2. Lentiviral vectors
The optimized chondroitinase gene was inserted into three
lentiviral vectors (Table 1). The vectors are collectively referred
to as LV-ChABC, and individually named LV-C and LV-D (with
the cytomegalovirus immediate-early [CMV] promoter) and LV-P
(with the mouse phosphoglycerate kinase [PGK] promoter for more
long-term expression in neurons). All the vectors are integrating
self-inactivating vectors and pseudotyped with VSV-G. The vectors
were made by standard techniques, after ﬁrst subcloning the chon-
droitinase transgene into a transfer plasmid such that the transgene
could be transcribed into a packageable RNA upon transfection into
HEK293T cells along with non-recombining plasmids that express
lentiviral and VSV-G genes (Naldini et al., 1996a; Dull et al., 1998).
Each transfer plasmid speciﬁes a vector RNA which contains,
from 5′ to 3′, the RU5 fragment of the long terminal repeat (LTR),
HIV-1 packaging signal in a Gag gene fragment, Rev response ele-
ment, central polypurine tract/central termination sequence, CMV
or PGK promoter with transgene, woodchuck hepatitis virus post-
transcriptional regulatory element, and self-inactivating (SIN) 3′
2 oscien
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TR. The vector RNAs are essentially identical except for the pro-
oter, polylinker and transgene. Vectors LV-C and LV-D were both
reated with the transfer plasmid pRRL (Dull et al., 1998), contain-
ng the CMV  promoter, with the chondroitinase transgene inserted
etween the XbaI and NheI sites. Vector particles were generated
y cotransfection of HEK293T cells with the transfer plasmid and
wo other plasmids (for LV-C: the VSV-G envelope protein vector
MD.G.2 and the viral core packaging construct pCMVR8.74; Dull
t al., 1998) or three other plasmids (for LV-D: Rev encoded on a
eparate plasmid; Dull et al., 1998). Vector LV-P was created with
 transfer plasmid derived from pRRL via the SIN-W-PGK vector,
ith the CMV  promoter replaced with the PGK promoter and dif-
erent polylinkers which includes an additional polypurine tract,
nd vector particles were generated by cotransfection with this
lus two other plasmids (Déglon et al., 2000). Thus, LV-C and LV-P
ere produced with a second-generation system and LV-D with a
hird-generation system.
Viral particles were concentrated by ultracentrifugation and
he viral particle-containing pellet was resuspended in 0.1 M
hosphate-buffered saline pH 7.4 (PBS) or in Dulbecco’s modiﬁed
agle’s medium (DMEM), and stored at −80 ◦C until further use.
entiviral vectors were titered by a p24 antigen ELISA assay (Perkin
lmer), or by quantitative PCR (Yán˜ez-Mun˜oz et al., 2006), and then
y determining the transgene-expressing units on either HEK293T
ells or SCTM41 cells (Table 1).
.3. Cell culture and transduction
Cell lines and primary astrocytes were as in Muir et al. (2010).
o provide conditioned medium containing CSPGs as a substrate
or secreted chondroitinase, just-conﬂuent Neu7 cells were main-
ained in DMEM with Insulin/transferrin/selenium supplement
ITS3+; Sigma) for 48 h, and the medium collected. Otherwise, all
ells were grown in DMEM containing 10% fetal bovine serum plus
tandard concentrations of penicillin, streptomycin and fungazone.
For transduction with LV-ChABC, cells were passaged the pre-
ious day onto 35-mm dishes so as to be ∼50% to 70% conﬂuent
hen LV was added. LV was added (0.2–2.5 l of stock for titration,
.0 l ≈ 6–10 × 105 transducing units for western blots), diluted in
 small volume of medium plus polybrene to 8 g/ml. The medium
as changed after 24 h. After another 24 h, it was replaced with
erum-free Neu7 conditioned medium. This was  collected after
4 h, centrifuged to remove detached cells, and concentrated 5- to
0-fold by centrifugation in a Centricon-50 unit (Millipore), mixed
ith protease inhibitor cocktail (Sigma P8340), and frozen for sub-
equent electrophoresis. Meanwhile the cells were ﬁxed with 4%
araformaldehyde for immunocytochemistry.
Fixed cells were ‘blocked’ with PBS/2% sheep serum/0.3% Tri-
on X-100 for 2 h, then immunocytochemistry was performed with
abbit anti-chondroitinase ABC (Acorda Inc., 1:2000, pre-absorbed
y incubation with conditioned medium from Neu7 cells for 3 h
t room temperature). After washing with PBS, peroxidase-linked
oat anti-(rabbit Ig) (Vector Labs) was added at 1:200 in PBS/1%
heep serum/0.1% Triton X-100 for 1–2 h. After further washes, pos-
tive cells were visualized either by diaminobenzidine staining, or
y tyramide signal ampliﬁcation (1% Tyramide-488 green in ampli-
cation buffer plus 0.0015% H2O2 for 5 min). Some dishes were
ubsequently counterstained with bisbenzimide (Hoechst-33258)
o visualize all cell nuclei. Cell counts of diaminobenzidine-stained
ells were performed using a light microscope on >4 randomly
elected 1-mm2 ﬁelds per dish.
Western blots were performed as in Muir et al. (2010).  Anti-
odies were: mouse anti-NG2 (Santa Cruz sc33666 = mcAb 132.38),
iluted 1:1000; mouse anti-‘stub’ (Seikagaku, mcAb 1B5, 1:250);
abbit anti-chondroitinase ABC (Acorda Inc., 1:2000, pre-absorbed
s above). The anti-‘stub’ antibodies 1B5 and 2B6 sensitively detectce Methods 201 (2011) 228– 238
products of chondroitinase activity, as they recognize disaccharide
units (1B5: -di-0S; 2B6: -di-4S) that remain attached to the
CSPG core proteins after chondroitinase ABC has cleaved off most
of the GAG chains.
2.4. Animal surgery, tract tracing, and immunohistochemistry
2.4.1. Animal surgery
Male adult Lister Hooded rats aged 3 months from Charles
River were housed in groups in standard cages under a 12 h:12 h
light/dark cycle, with food and water ad libitum. All procedures
were performed in accordance with the UK Animals (Scientiﬁc Pro-
cedures) Act (1986). All surgical procedures were performed under
inhalation anesthetic isoﬂurane (1–2% in a mixture of 25% nitric
oxide and 50% oxygen). Body temperature was  maintained at 37 ◦C
during surgery using a heating pad.
2.4.2. Cortical injection
Rats were placed in a stereotactic head frame, and the bregma
was  exposed as reference. One hole was drilled through the skull,
and vector was  injected into the left cortex (coordinates: AP,
−0.5 mm;  ML,  −2.0 mm;  DV, +1.5 mm). Volume injected was 1.0 l
(LV-P being diluted 2-fold) ≈5–8 × 105 transducing units; saline
was  injected in controls. No obvious ill effects attributable to vec-
tor injection were observed. Expression was examined at 2, 4 and
8 weeks. All data are from at least 3 rats unless otherwise stated.
2.4.3. Spinal cord lesion
The spinal cord was  exposed with a laminectomy at level C4,
a small slit was made on the dura, and a pair of ﬁne forceps (Fine
Science Tool, #11253-20) was  positioned on either side of the dorsal
columns and pushed down vertically into the cord for 1.5 mm.  The
forceps were then held tightly together for 20 s before being raised
back out of the cord creating a crush lesion of the dorsal columns.
In animals given concurrent operations, the spinal cord lesion was
done ∼15 min  before the cortical injection of vector.
2.4.4. Intraspinal injection
In an additional series of animals, LV-C was injected into the
spinal cord lesion region instead of into the brain. Immediately
after the spinal cord lesion, two injections of 1 l of either LV-C
or surgical saline were carried out, 1 mm  below and 1 mm  above
the lesion site. The injections were made through a pulled glass
capillary (borosilicate thin wall with O.D. 1.0 mm and I.D. 0.78 mm,
Harvard Instruments BS4 30-0039) of which the tip end that enters
the spinal cord has a diameter of ∼20 m.  The opposite end was
connected to 30 cm of polyethylene tubing (I.D., 0.40 mm)  which
was  backﬁlled with mineral oil (Sigma) and linked to a syringe
driven by a microdrive pump (Syringe Infusion Pump 22, Harvard
Apparatus, Kent, UK). The glass capillary was ﬁrst lowered verti-
cally for 2 mm then raised for 0.5 mm,  then infusion started and
lasted for 5 min. Infusion rate was  set at 200 nl/min. The capillary
was  then left to stand in place for another 3 min  before being lifted,
to allow complete absorption.
2.4.5. Anterograde axon tract tracing
The corticospinal tract (CST) was  traced with cortically injected
biotinylated dextran amine (BDA). The BDA injection was  wider
than the original LV-ChABC injection to ensure good uptake, which
might be impeded by glial scarring in the original injection track.
About 2 weeks before termination of experiments, the animals
were deeply anesthetized with isoﬂurane and secured in a stereo-
taxic frame. With a dental drill, three holes were made in the skull
over the forelimb representation in the sensorimotor cortex, and
1 l of 10% BDA (MW  10,000, Molecular Probes, in 10 mM  PBS) was
injected slowly using a 26-gauge Hamilton syringe at a depth of
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Fig. 1. Western blots showing that active chondroitinase is secreted following transduction of tissue culture cells with the lentiviral vectors. Neu7 conditioned medium (a
source of CSPGs) was placed on transfected cells for 24 h, then analyzed by western blotting. (a) LV-C and LV-D. The ﬁrst two lanes are positive and negative controls with Neu7
medium  not exposed to transfected cells; lane 1 was digested in vitro with commercial chondroitinase (Sigma, 20 mU, 37◦ , 3 h). (Top panel) Probed for carbohydrate ‘stub’
epitope produced by chondroitinase action (antibody 1B5). Neu7 conditioned medium (lane 2) shows little immunoreactivity, but incubation with cells after transduction
with  LV-ChABCs generates extensive reactivity. (Middle) Probed for NG2. Undigested NG2 (lane 2) appears largely as a characteristic ‘smear’ above the core protein band due
to  the heterodispersed high-Mr GAG chains, and this is all converted to core protein by digestion with commercial chondroitinase (lane 1) or by incubation with cells after
transduction with LV-ChABC. (Bottom) Probed for chondroitinase ABC. Commercial chondroitinase (lane 1) shows both full-length band (Ch) and a shorter band (Ch**) due
to  proteolytic activity during incubation with medium. LV-ChABC all generate a diffuse chondroitinase band (GlyCh: partially glycosylated): this migrates more slowly than
bacterial  chondroitinase, conﬁrming that it has some glycosylation at sites which were not mutated. Some lanes are overexposed as the experiment was principally intended
to  detect digestion of CSPGs; also see (c). Black bar or star indicates intense bands which partially bleached during imaging. (b) LV-GFP (control) and LV-P. (Top) Probed for
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.5 mm at each site. (Stereotaxic coordinates: AP +0.5, ML  −2; AP
0.5, ML  −3; AP −0.5, ML  −1.8.) After the last injection, the skin
as sutured and the animals were returned to standard housing
onditions for 14–19 days.
.4.6. Tissue preparation
Animals were sacriﬁced by sodium pentobarbital overdose
200 mg/kg intraperitoneally), and transcardially perfused with PBS
ollowed by 4% paraformaldehyde in 0.1 M phosphate buffer. The
rains and spinal cords were then post-ﬁxed in the same ﬁxative
vernight at 4 ◦C, followed by 30% sucrose in phosphate buffer
vernight at 4 ◦C. Tissue was frozen in optimized cutting agent
OCT) before cutting. For brain tissue, and spinal cord at C1, coronal
ections 40 m thick were cut with a freezing microtome and kept
ree-ﬂoating at 4 ◦C. Spinal cord below C1 was cut in parasagittal or
orizontal plane at 30 m.
.4.7. Fluorescent immunostaining
Tissue sections were stained with antibodies 2B6 (as above)
r CS56 (Sigma; 1:400), or Wisteria ﬂoribunda agglutinin (WFA;
igma; 1:150). Sections were ‘blocked’ for 1 h with TBST (Tris-
uffered saline with 0.1% Triton-X100) plus 10% goat serum, then
00–300 l primary antibody at appropriate dilution in block-
ng buffer was added to each well and the plates were gently
haken overnight at 4 ◦C. Sections were then washed in TBST for
× 30 min  at RT before secondary antibodies were added to wells
or 2 h at RT. For BDA, ﬁnal detection was with Streptavidin Alexa
luor 488 conjugate (Invitrogen). After further washes, sections
ere mounted onto 1% gelatin coated glass slides, covered with
luorSaveTM mounting medium (Merck, #345787), and coverslip..4.8. Quantiﬁcation of axon sprouting, retraction, and
egeneration
Axon sprouting was quantiﬁed by drawing 6 lines in the
ray matter, parallel and 100 m apart, from 1.0 mm  to 1.5 mmes according to cell type, is all reduced to core protein following LV-P transduction.
) Commercial chondroitinase (Sigma); (2) medium from HEK cells transduced with
rostral to the lesion front (the rostral edge of the lesion cavity), as
shown in Fig. 5a. The number of axons that crossed each line was
counted on 4–7 sections per animal; the number of crossings of
all 6 lines were summed as the total sprouting number; the axon
number in a transverse section at C1, ∼2 mm rostral to the lesion,
was  counted as the total labeled axon number (to account for the
inter-animal BDA tracing variability); and sprouting number was
normalized against the total labeled axon number and the number
of sections to give the axon sprouting index. To quantify retrac-
tion and regeneration, 10 lines were drawn transversely (Fig. 5a),
and the number of traced axons crossing each line was  counted,
and calculated as the percentage of the total labeled axon number.
The same procedures were used for animals with LV injected into
brain (Fig. 5) or spinal cord (Fig. 6). Controls with saline injections
in either location showed indistinguishable axon distributions and
were therefore combined for analysis. Signiﬁcance was  assessed by
two-tailed t-tests.
2.5. Enzyme activity assay
Animals received LV-ChABC injection to cerebral cortex as
above. After 2 or 4 weeks they were sacriﬁced by sodium pentobar-
bital overdose, and a 3-mm cube of cortex from the injected area,
and an equivalent sample from the contralateral side, were dis-
sected and frozen and subsequently homogenized in enzyme buffer
for total enzyme activity assay (Lin et al., 2008). Polyacrylamide
discs of 3.5 mm  diameter, each containing 7.5 g of chondroitin sul-
fate (CS-A, Sigma), were incubated with the homogenates for 1 h at
37 ◦C. A range of standard quantities of commercial chondroitinase
ABC (Seikagaku) was used as a positive control. (One unit generates
one micromole of unsaturated disaccharide from chondroitin-6-
sulfate per minute at 37 ◦C, pH8.0.) After incubation, the discs were
rinsed brieﬂy with water, ﬁxed in 40% methanol:8% acetic acid, and
stained with 0.2% Alcian blue 8GX (Sigma) for 30 min. Discs were
232 R.-R. Zhao et al. / Journal of Neuroscience Methods 201 (2011) 228– 238
Fig. 2. Immunocytochemistry showing expression of the vectors in tissue culture cells. Cells were transduced with lentiviral vectors, ﬁxed, reacted with antibody against
c s, 100
i  cultu
t
t
3
3
t
u
t
(
r
a
2
s
(
chondroitinase, and visualized with peroxidase diaminobenzidine reaction. Scale bar
n  HEK293T cells, Neu7 cells, and primary astrocytes. Bottom row: negative control
hen examined for loss of color due to the digestion of CS relative
o the negative control.
. Results
.1. Validation of lentiviral vectors in tissue culture
To investigate whether the lentiviral vectors could successfully
ransfect cells and secrete functional chondroitinase enzyme, we
sed them to transduce several cell lines and primary astrocyte cul-
ures. Chondroitinase production was assessed by western blotting
Fig. 1) and immunocytochemistry (Fig. 2).
For western blotting, 2 days after adding vector, the medium was
eplaced with conditioned medium from Neu7 cells, which contains
bundant CSPGs to serve as a substrate. This medium was collected
4 h later and chondroitinase activity was assessed by western blots
howing degradation of CSPGs (Fig. 1):
(i) by degradation of NG2 proteoglycan;
(ii) by production of disaccharide ‘stub’ immunoreactivity (anti-
body 1B5);
iii) by direct detection with antibody against chondroitinase ABC.
All three vectors showed successful expression in HEK293T
ells, rat glial cell lines, and primary astrocytes. The NG2 and m.  Top row: LV-D in HEK293T cells, Neu7 cells, and SCTM41 cells. Middle rowLV-P
res with no vector.
1B5 antibodies showed essentially complete digestion of the gly-
cosaminoglycans of the CSPGs in each sample. The chondroitinase
antibody showed that the amount of secreted protein was con-
siderably greater than with earlier experiments using plasmid
transfection (Muir et al., 2010). It was especially proliﬁc in HEK293T
cell cultures transduced with LV-C or LV-D, which employ the CMV
promoter. The amount of chondroitinase seen on a western blot
from LV-C-transduced HEK293T cells was equivalent to ∼1 mU of
commercial chondroitinase per 5 l of medium (Fig. 1c).
Transduction was  also visualized directly by immunocytochem-
istry with antibody against chondroitinase ABC (Fig. 2). Positive
cells were clearly identiﬁed by stained cytoplasm contrasting with
well-deﬁned unstained nuclei. There was a wide range of inten-
sities and it is possible that some cells secreting chondroitinase
were not visualized, especially in the more conﬂuent cultures.
Therefore, the titres deduced from these cultures (Table 1) are con-
sidered to be lower limits. LV-P (with chondroitinase under the PGK
promoter) gave similar high transduction efﬁciencies in several dif-
ferent cell types: HEK293T cells, Neu7 cells (astrocyte-derived),
SCTM41 cells (Schwann cell-derived), and primary astrocytes.
LV-C and LV-D (with the CMV  promoter) also transduced all
these cell types well but the titres were severalfold higher on
HEK293T cells than the others. As expected with integrating lentivi-
ral vectors, expression persisted after passaging the transduced
cells.
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Fig. 3. In vivo LV-ChABC injection into the rat cortex results in chondroitinase activity and the activity is also transported along axons. Injection was into deep layers of cortex
on  the left. Scale bar, 1 mm.  (a–c) LV-C, 2 weeks: adjacent coronal sections from one brain stained for chondroitinase-produced stub (a), perineuronal net (b) and chondroitin
sulfate  (c). Chondroitinase digestion (area outlined with red arrows) is seen around the injection site and in the cortical white matter and adjacent hippocampus. On  the
original of (a), a faint column of reactivity can also be seen in the contralateral cortex. M, midline. (d–f) LV-C, 4 weeks: a similar series of sections, showing that chondroitinase
digestion has extended along axon tracts and to the contralateral cortex. (g,h) LV-GFP, 4 weeks: similar sections from a brain injected with a lentivector encoding farnesyl-GFP;
4  weeks; stained with antibody against GFP. (g) Cortex near injection site, showing strong expression in astrocytes at surface (A), and oligodendrocytes in white matter/corpus
callosum (O), and large numbers of neuronal ﬁbers (N). (h) High-power views of contralateral side showing GFP-positive axons that have crossed in the corpus callosum and
(inset)  ascending in the cortex opposite the injection site. (i) Enzyme activity assay of functional chondroitinase level 4 weeks after LV injection into the cortex. Disks were
loaded  with equal amounts of chondroitin sulfate (CS) and each was  incubated with extract of cortex from one brain to allow digestion by chondroitinase expressed in the
sample. They were then stained for CS. Top row: incubated with extract of control brain (0), and with various amounts of commercial chondroitinase (12.5–100 mU). Bottom
panels:  incubated with extracts of LV-injected brains. All samples from the injected side gave some digestion, especially the 4-week samples, as did the 4-week samples from
the  opposite side. (j,k) 2B6 staining on spinal cord after LV-P cortical injection. (j) 2 weeks: horizontal section at level C3-C4. (k) 4 weeks: transverse section at level C1. M,
midline. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Expression of chondroitinase in rat brain from different LVs at different
times: coronal sections stained with Ab-2B6 as in Fig. 3. Scale bar, 1 mm.  (a) LV-P, 2
weeks: there is widespread digestion on both sides (red arrows). White arrow marks
the  approximate position of the injection. (b) LV-D, 4 weeks: more circumscribed
digestion within ∼0.5 mm of the injection track, but also strong digestion within34 R.-R. Zhao et al. / Journal of Neur
.2. Injection of lentiviral vectors into rat cortex produces
hondroitinase activity locally and along axons
To assess in vivo activity, each LV-ChABC was injected into
he left cortex of adult rat brain, and the effects were examined
t 2, 4 and 8 weeks, using antibody 2B6 to detect the carbohy-
rate ‘stub’ residue of chondroitinase digestion (Figs. 3 and 4).
imilar results were seen with all three vectors and so they are
escribed together, although the spatial extent of digestion was
enerally greatest with LV-P and least with LV-D. CSPG degrada-
ion was evident by 2 weeks (n = 5): the digestion region stained
ith Ab-2B6 spanned all cortical layers and part of the hippocam-
us (Fig. 3a). In the same region there was a strong reduction
n chondroitin sulfate level detected by antibody CS56 stain-
ng (Fig. 3c), and elimination of the perineuronal nets whose
ain components are CSPGs linked to hyaluronan, as detected
y Wisteria hemagglutinin (Fig. 3b). In a typical brain injected
ith 1 l of LV-C, the digested region measured 3.5 mm  in the
nterior–posterior direction at 2 weeks. Four weeks post-injection
n = 6), the chondroitinase degradation zone stained with Ab-2B6
ad spread laterally in the injected cortex, and was also present
n the corpus callosum (cortical axon tract crossing the midline),
nd in the contralateral cortex in a column opposite the injec-
ion site (Fig. 3d). This extended distribution indicates secretion of
hondroitinase from commissural axons. The degradation residue
as still present by week 8 (n = 3) with even broader distribu-
ion but uneven and generally weaker (Fig. 4c), presumably due
o a balance between induction, degradation, and resynthesis of
SPGs.
To test directly whether a lentiviral vector could lead to expres-
ion of its product in axons crossing to the contralateral cortex,
n animal was injected with a lentiviral vector encoding farne-
yl green ﬂuorescent protein (GFP) into the same position of the
ortex, and GFP expression was examined by immunohistochem-
stry at 4 weeks. GFP was  expressed at high levels in glia around
he injection track and in the cortical white matter, and also in
umerous nerve ﬁbers throughout the thickness of the cortex
n the injected side (Fig. 3g). Some GFP-positive axons extended
hrough the corpus callosum, and some were also seen ascending
n the contralateral region of cortex, conﬁrming that the transgene
roduct can be distributed to that location by commissural axons
Fig. 3h). No 2B6 staining was present in the GFP-positive regions,
onﬁrming that the lentiviral vector itself does not induce CS
egradation.
The enzyme activity level at 2 and 4 weeks was studied in
ne set of brains using CS digestion assay in gel circles (Lin et al.,
008). A 3-mm cube of cortex from the injected area and the
quivalent volume from the contralateral side were dissected and
rozen and subsequently homogenized for total enzyme activity
ssay. Lighter color indicates that the enzyme activity of that sam-
le is stronger (Fig. 3i). LV-C already produced active enzyme
t 2 weeks, and by week 4 the activity was also detectable in
he contralateral cortex. LV-P produced a similar pattern but the
ctivity level was lower. The total amount present in the LV-C-
njected cortex at 4 weeks is estimated as ∼25 mU from this assay,
nd the distribution is consistent with the 2B6 immunostaining
esults.
Since CS degradation in brain was observed to have spread
hrough the corpus callosum axons, we also looked for it in the
orticospinal tract (CST) in two animals with LV-P injection into
he left cortex. Sections of spinal cord stained with Ab-2B6 showed
hat degradation residue was present in the right CST, i.e. the tract
rising from the injected area, and it extended down to C4 level
Fig. 3j and k). Speciﬁc 2B6 staining was not seen outside the
ST.
the corpus callosum extending to the contralateral side. (c) LV-C, 8 weeks: patchy
digestion in various regions, especially ipsilateral hippocampus (Hipp) and thala-
mus  (Thal). (d) PBS-injected control, 4 weeks: no speciﬁc immunoreactivity. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web  version of this article.)
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Fig. 5. In animals given a spinal cord lesion, LV-ChABC injected into cerebral cortex enhances corticospinal axon growth towards the lesion and lateral axon sprouting.
Horizontal sections of spinal cord at the level of the dorsal columns are shown, 4 weeks after lesion ± LV-P cortical injection, stained for BDA, which had been injected into
cortex  to trace the CST. Cranial at top; lesion cavity at bottom in (a–c). M,  midline. Images are laterally inverted, so the right CST (labeled from the left cortex) is shown to the
left.  Scale is indicated in (a); scale bars 100 m for other panels.
(a)  Methods to quantify retraction, regeneration and sprouting. Spinal cord at C3-C4 from a lesioned animal with no vector treatment. At bottom, grid for measuring
longitudinal retraction/regeneration relative to the lesion front (the rostral edge of the lesion cavity). At top, grid for measuring lateral sprouting in gray matter (gm) relative
to  the edge of the white matter (wm). (b) Control spinal cord lesion without LV injection: axons have retracted from the cranial edge of the lesion cavity (retraction bulbs
arrowed). (c) In animals which received LV-P cortical injection, axons grow along the lesion edge caudally (arrowed). (d) Spinal cord 1.0–1.5 mm above the lesion, just left
of  the midline, in a control lesioned animal; axons show little lateral sprouting. (e) Similar section in a LV-P-treated animal shows substantial lateral sprouting into the gray
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catter.  (f) Measurements of longitudinal retraction/regeneration: percentage of ax
V-treated CST (±SEM). Signiﬁcance by t-test: *P < 0.05; **P < 0.01. (g) Measurement
V-treated CST. Signiﬁcance, P < 0.05. (h) Diagram of the surgical procedures.
.3. Cortical injection of lentiviral vector enables axon
reservation and sprouting after spinal cord injury
The effect of the LV-ChABC cortical injection on lesioned axons
as studied with the CST of spinal cord injured rats (Fig. 5). A bilat-
ral dorsal column crush lesion at C4 level was made, then LV-P, or
aline in the control group, was injected unilaterally into the cortex
uring the same surgery (n = 3 per group). Subsequently, the axons
ere traced with cortical BDA injection, then animals were per-
used at 4 weeks post-lesion. This operation totally severs the main
ract of CST axons, in the dorsal columns, and a roughly oval cavity
orms in the lesion area. Effects on the axons on the rostral side
ere evaluated by two criteria: the number of axons regenerated
n the caudal direction, and the number of axons sprouted laterally
nto the gray matter. The method of quantiﬁcation is illustrated in
ig. 5a. In the control saline-injected group, axons retracted ros-
rally for several hundred microns and formed retraction bulbs at
he tips (Fig. 5b and f). In contrast, in the LV-P group, the axons had
ewer retraction bulbs, and some extended along the edge of the
avity and grew caudally (Fig. 5c and f), reaching up to 500 m alonghich remain at various distances above and below the lesion front, for control and
teral axon sprouting index (per section per 100 axons labeled, ±SD), for control and
the edge. The difference in distribution was statistically signiﬁcant
(Fig. 5).
Axon sprouting laterally into the gray matter was  also enhanced
by the LV-P treatment. Compared to the saline control group,
a larger number of axons crossed the gray matter/white matter
boundary, and the ﬁber length within the gray matter was increased
(Fig. 5d,e, and g). The sprouting index in the LV-P group was
3.15 ± 0.48 (SD), signiﬁcantly more than that in the control group
which was 1.32 ± 0.07 (P < 0.05).
3.4. Spinal cord injection of lentiviral vector after spinal cord
injury produces similar improvements
We next asked whether local injection of LV-ChABC into the
injured spinal cord, which would generate chondroitinase locally
from transduced glia as well as possibly from neurons, would have
similar effects to cortical injection, which delivered chondroitinase
to the injury site speciﬁcally via the corticospinal axons. For this
purpose, the same bilateral dorsal column crush lesion was made
at C4 level, and immediately afterwards, two  injections of LV-C
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Fig. 6. Intraspinal LV-ChABC injection promotes axon sprouting and growth in lesioned spinal cord. Procedures and illustration formats are as for Fig. 5, except that instead
of  LV-P injection into the brain, LV-C was injected into the spinal cord at the cranial and caudal edges of the lesion. (a) Diagram of the surgical procedures. (b–e) Horizontal
sections of spinal cord, 4 weeks after lesion ± LV-C injection, stained for BDA, which had been injected into cortex to trace the CST. Cranial at top. M,  midline; gm,  gray
matter;  wm,  white matter. Scale bars, 100 m.  (b) Control spinal cord lesion with saline injection: axons have retracted from the lesion front. (c) In a LV-C-treated animal,
axons  show little retraction, and some grow along the lesion edge. (d) Spinal cord 1.0–1.5 mm above the lesion in a control animal; axons show little lateral sprouting. (e)
Robust axon lateral sprouting into the gray matter in a LV-C treated animal. (f) Measurements of longitudinal retraction/regeneration, at 4 weeks: percentage of axons which
remain  at various distances above and below the lesion front, for control and LV-treated CST (±SEM). Signiﬁcance by t-test: *P < 0.05; **P  < 0.01. (g) Measurements of lateral
axon  sprouting index (per section per 100 axons labeled, ±SD), for control and LV-treated CST, at 4 weeks (top) and in a separate group of animals at 2 weeks (bottom).
Signiﬁcance, P < 0.01.
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ere given at 1 mm caudal and 1 mm  rostral to the lesion, totalling
 l  (6 × 105 units). Control animals were given the same lesion but
eceived saline injections instead of vector. Subsequent staining
ith Ab-2B6 antibody conﬁrmed that there was a wide zone of
SPG degradation product around the lesion in the LV-C injection
roup but not in control animals (data not shown).
The CST axons were traced with bilateral BDA cortical injection,
nimals were perfused 4 weeks post-lesion, and axon retraction
nd sprouting were examined as before (Figs. 5a and 6). The results
ere the same as with cortical LV-ChABC injection and spinal cord
esion. In the control group, axons had retracted from the lesion
ront, and retraction bulbs were found at the axon endings (Fig. 6b).
ith the LV-C injection, the CST axons were present right up to
he cavity, and some extended a few hundred micrometers along
he lesion edge past the lesion front (Fig. 6c). These ﬁbers showed
 tortuous shape instead of a smooth path, consistent with their
eing regenerated ﬁbers. Local delivery of LV-C allowed more than
% axon ﬁbers to grow pass the lesion front and extended for up to
00 m (Fig. 6f).
Local delivery of LV-C also signiﬁcantly enhanced the lateral
prouting of axons above lesion. At 4 weeks, the sprouting index
n the LV-C group was 3.06 ± 0.27 (SD), more than double that in
he control group which was 1.36 ± 0.11 (Fig. 6g; P < 0.01). Another
roup of animals was operated in the same way and examined at 2
eeks, and they also showed signiﬁcantly more sprouting in the LV-
 group (1.58 ± 0.09) than the control group (1.14 ± 0.09; Fig. 6g;
 < 0.01). The sprouting index at 2 weeks was lower than at 4 weeks,
onsistent with the axon sprouts continuing to grow during this
eriod, while the chondroitinase gene is still being expressed.
Although lentiviral vectors generally produce few adverse
ffects, we wished to check whether the LV-ChABC vectors specif-
cally produced inﬂammation following injection into the CNS. For
his purpose, sections of spinal cord from several animals in each
roup were stained with antibody OX42, to visualize microglia and
acrophages, and with antibody against GFAP, to visualize astro-
ytes (data not shown). The same pattern was  seen in lesioned
pinal cords that had been injected with saline (2 or 4 weeks, n = 4),
r with LV-C (2 or 4 weeks, n = 3), or with LV-P (2 or 4 weeks,
 = 3; these animals were not BDA traced). They showed that both
icrogliosis and astrocytosis were restricted to a zone ∼0.5 to 1 mm
ide around the lesion edge, except in the dorsal columns rostrally
and occasionally, to a lesser extent, caudally) where microglio-
is was observed for a long distance; this is normally seen in such
esioned animals due to the degeneration of myelinated axons dam-
ged by the crush lesion. Thus, the extent of inﬂammation in the
V-ChABC injected animals was similar to or less than the inﬂam-
ation in the controls.
. Discussion
These experiments demonstrate that a combination of selective
utagenesis to ablate cryptic N-glycosylation sites, and expres-
ion in lentiviral vectors, allows the bacterial chondroitinase ABC
nzyme to be copiously expressed in mammalian CNS.
Chondroitinase activity (as shown by the presence of 2B6 stub
mmunoreactivity) was detected in injected brains for up to 8
eeks, the longest time point assessed. This probably represented
ontinuing production of active enzyme up to that time, as it
xtended well beyond the areas labeled at 4 weeks. Active enzyme
as detected directly from brains at 4 weeks by enzyme activity
ssay. We  estimate that one l of vector (6–10 × 105 transducing
nits) generated several tens of milliunits of enzyme in injected
rain in this assay (Fig. 3g), and a similar quantity in condi-
ioned medium of cultured glial cells after 3 days by western blots
Fig. 1).ce Methods 201 (2011) 228– 238 237
Prior studies with lentiviral vectors in the CNS have shown that
they transduce all types of glial cells and neurons, with neuronal
expression predominating from 2 weeks onwards. In the case of
the chondroitinase vectors, the pattern of chondroitinase diges-
tion indicates that the enzyme is being secreted from neurons,
because glial transduction could not account for the widespread
chondroitinase activity, including in long-distance axonal projec-
tions: the corpus callosum and the corticospinal tract. It was not
possible to visualize chondroitinase production directly as the
antibody, which stained transduced subconﬂuent cells in tissue
culture, did not stain transduced cells in over-conﬂuent cultures
nor in sections from injected brains. However, a GFP-transduced
brain conﬁrmed that a lentiviral vector can indeed express its
product in the decussating axons that pass through the corpus
callosum.
Lentiviral vectors do not themselves produce signiﬁcant inﬂam-
mation nor an immune response (Bloemer et al., 1997; Baekelandt
et al., 2002), if a puriﬁed preparation is used, and we did not observe
astrocytosis in the chondroitinase-expressing areas of brain beyond
that attributable to the injection itself. Likewise in spinal cord,
astrocytosis and microgliosis covered a region no greater than
that seen in control lesioned spinal cords, the glial reactions being
attributable to the crush lesion rather than the vector. There were
also no obvious behavioral anomalies attributable to the vector
injections.
The results in spinal cord injury can be compared with those of
Bradbury et al. (2002),  who performed the same spinal cord lesion
followed by intermittent infusion of 300 mU of chondroitinase
intrathecally over 10 days. Both treatments prevented retraction of
the severed CST axons from the lesion (at the time-points assessed),
and produced signiﬁcant regeneration of CST axons along the edge
of the lesion cavity, and lateral sprouting of CST into the gray matter.
Thus, within the 4-week timescale of our axon tracing experiments,
the results appear to be similar, whether the vector is delivered to
the cortex or to the spinal cord.
Bradbury et al. (2002) also found more extensive regeneration of
axons, for >4 mm,  at 8–10 weeks, and this was accompanied by sig-
niﬁcant behavioral recovery. We  are now undertaking longer-term
experiments to directly compare lentiviral treatment with serial
infusion, and to assess behavioral as well as anatomical recovery,
and to test whether lentiviral vector delivery is equally (or more)
effective if given some time after the lesion.
The present results indicate that delivery of chondroitinase by a
lentiviral vector to the cerebral cortex generates substantial chon-
droitinase activity locally, and signiﬁcant activity in long-range
axon projections, attributable to enzyme transport down axons. In
animals with lesioned CST, the enzyme has a beneﬁcial effect on
the severed axons that is comparable in effect to direct infusion,
and likely to be much more suitable for therapeutic use. In con-
trast to injection or infusion, the lentiviral vector only has to be
administered once; it confers greatly reduced risks of mechanical
damage, inﬂammation, and infection at the infusion site; it gen-
erates enzyme continuously within the CNS tissue, including axon
tracts; and it is effective for a long period. It can now be combined
with other treatments in long-term animal models, to overcome
other inhibitory agents in the injured CNS and to enhance the regen-
erative ability of neurons, in order to work towards a combination
therapy suitable for human patients.
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